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Recent randomized trials in acute myocardial infarction 
suggest that infarct size reduction need not be achieved for 
intravenous streptokinase to improve patient survival. If 
this is the case, attempts to achieve late revascularization 
may be justified. To assess the results of late primary 
coronary angioplasty performed in the setting of acute 
myocardial infarction, the clinical and angiographic data as 
well as hospital outcome of 139 consecutive patients treated 
with coronary angioplasty without prior thrombolytic ther- 
apy 6 to 48 h after the onset of chest pain (late group) were 
compared with those of 117 patients treated with primary 
angioplasty <6 h after the onset of chest pain (early group); 
time to angioplasty was assessed as a covariate of survival. 
In the 139 patients treated ~6 h after the onset of chest 
pain, the mean age (2 SD) was 57 + 12 years and the 
median time to angioplasty was 15 h; 61% had multivessel 
disease, 14% were in cardiogenic shock and the mean left 
ventricular ejection fraction was 44 2 12%. Angioplasty 
was successful (final diameter stenosis ~70% and Throm- 
bolysis in Myocardial Infarction [TIMI] flow grade 22) in 
78% of patients. Successful angioplasty was associated with 
a 5.5% in-hospital mortality rate, whereas unsuccessful 
angioplasty was associated with a 43% hospital mortality 
rate ( p < 0.001). 
Multivariate testing in all patients identified four inde- 
pendent predictors of in-hospital death: cardiogenic shock 
(p < O.OOl), unsuccessful angioplasty (p = O.OOl), ejection 
fraction 530% (p = 0.002) and patient age (p = 0.004). 
Time to angioplasty was not a predictor of outcome (p = 
0.56). Unsuccessful angioplasty, however, was associated 
with a particularly high mortality rate in patients with 
anterior infarction or ejection fraction 130%. Thus, late 
emergency angioplasty may be justified when the likelihood 
of angioplasty success is very high. Randomized trials are 
needed to assess the utility of late coronary reperfusion in 
the setting of acute myocardial infarction. 
(J Am Co11 Cardiol1989;13:1122-6) 
Although time-dependent myocardial salvage is generally 
thought to be the mechanism by which reperfusion therapy 
improves survival in patients with acute myocardial infarc- 
tion (l), recent randomized trials (2,3) have shown a survival 
benefit without a demonstrated or expected reduction in 
infarct size or improvement in left ventricular function. This 
has led to the concept that myocardial reperfusion, even if 
established relatively late in the course of acute myocardial 
infarction, may be of benefit, perhaps by decreasing malig- 
nant arrhythmias (4), by improving infarct healing (5) or by 
other means. If this is the case, then attempts to reestablish 
arterial patency in selected patients who present to the 
hospital relatively late in the course of infarction may be 
justified. 
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To assess the results of late primary coronary angio- 
plasty, we reviewed the clinical and angiographic data and 
hospital outcome of 139 consecutive patients treated with 
primary coronary angioplasty 6 to 48 h after the onset of 
chest pain (late group) and compared their outcome with that 
of 117 consecutive patients treated with primary angioplasty 
within 6 h of symptom onset (early group). 
Methods 
Study patients. The late study group comprised 139 pa- 
tients with acute myocardial infarction treated by angio- 
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plasty without prior thrombolytic therapy 6 to 48 h after the 
onset of symptoms at the University of Michigan from 1983 
until the end of December 1987. Thirteen other patients were 
excluded because their procedural cineangiogram was un- 
available for review (n = 9) or the pre- or postdilation 
cineangiogram was of insufficient quality to allow for quan- 
titative analysis (usually because the angiographic guide wire 
was placed across the stenosis that had been dilated) (n = 4). 
Twenty-six of the patients had participated in a previously 
reported randomized trial (6) assessing interventions in acute 
myocardial infarction. The results in the study group were 
compared with those from all 117 patients treated with 
primary coronary angioplasty (no prior thrombolytic ther- 
apy) within 5.9 h of the onset of chest pain who otherwise 
met the same criteria. 
During this time period, several randomized trials (7,8) 
assessing the efficacy of thrombolytic therapy in the setting 
of acute myocardial infarction were underway. The exclu- 
sion from these trials of patients older than 75 years and with 
cardiogenic shock may have increased the mix of such 
patients referred for primary angioplasty. Coronary angio- 
plasty was performed after patients gave informed consent 
and under guidelines approved by the Committee to Review 
Clinical Research and Investigation at the University of 
Michigan Medical Center. 
Indications for angioplasty. All patients underwent coro- 
nary angioplasty on the basis of clinical evidence of ongoing 
ischemia (persistent precordial, arm or neck discomfort or 
electrocardiographic ST or T wave changes) or hemody- 
namic compromise. Patients were usually not considered to 
be eligible for angioplasty if they had 260% diameter steno- 
sis of the left main coronary artery, 270% stenosis of both 
the proximal left anterior descending and left circumflex 
coronary arteries or distal occlusions in tortuous vessels that 
were not believed to be technically suitable for the proce- 
dure. Patients were not necessarily excluded because of 
advanced age or poor left ventricular function and, in fact, 
the concurrent presence of clinically evident severe left 
ventricular dysfunction in patients >6 h after the onset of 
chest pain often prompted referral for cardiac catheteriza- 
tion and angioplasty. 
Angioplasty technique. The technique of coronary angio- 
plasty utilized has been previously described (6). Briefly, all 
patients received sublingual nitroglycerin (400 pg) to exclude 
coronary spasm and intravenous morphine for chest pain, 
and all had cardiac catheterization performed after the 
placement of vascular sheaths and administration of 3,000 to 
5,000 U of heparin. After it was determined that a patient’s 
coronary anatomy was suitable for angioplasty, an additional 
5,000 to 7,000 U of intravenous heparin was given and 
angioplasty was performed. After adequate reduction of the 
stenosis had been accomplished, patients were treated with 
intravenous heparin (for 3 to 10 days), aspirin (80 to 600 mg 
daily) and an oral calcium channel blocker and nitrate (as 
tolerated). All patients were initially monitored in the inten- 
sive care unit. Hemodynamic monitoring was performed, 
and adjunctive treatment was administered as clinically 
indicated. 
Clinical variables. Clinical data had been prospectively 
entered onto case report forms at the time of the catheter- 
ization Case report forms and patient charts were reviewed 
by an independent observer, unaware of angiographic and 
in-hospital outcome, to assure completeness and accuracy of 
the data. Ten clinical variables were analyzed for all pa- 
tients: 1) age; 2) gender; 3) diabetes mellitus; 4) prior 
myocardial infarction; 5) infarct site (anterior or inferior/ 
posterior): 6) time from onset of chest pain to coronary 
angioplasty; 7) systolic blood pressure on arrival in the 
cardiac catheterization laboratory; 8) presence of cardioge- 
nit shock (defined as systolic blood pressure after volume 
replacement 580 mm Hg without, or 589 mm Hg with, the 
use of an intravenous inotropic agent or balloon counterpul- 
sation support); 9) postangioplasty recurrent ischemia (de- 
fined as the need for repeat angioplasty or bypass surgery, a 
secondary increase in creatine kinase isoenzymes or silent 
total occlusion of the site dilated found on predischarge 
angiography): and 10) in-hospital death. Additional data 
were retrieved and analyzed retrospectively for patients who 
had died after angioplasty; these included time from angio- 
plasty until death, peak creatine kinase level, cause of death 
and necropsy results. 
Angiographic variables. The following angiographic var- 
iables were entered prospectively at the time of catheteriza- 
tion by observers unaware of clinical outcome: pre- and 
postangioplasty percent diameter stenosis measured with 
use of a computer-assisted quantitative angiographic system 
(9), and pre- and postangioplasty Thrombolysis in Myocar- 
dial Infarction (TIMI) coronary flow grade (10). 
Statistical analysis. Data were entered into the University 
of Michigan PTCA for Acute Infarction Database, a rela- 
tional data base that uses SYSTAT software (11). 
Data are presented as mean values t SD except where 
noted. Unpaired Student’s t tests and chi-square analyses 
were used to compare continuous and categorical single 
variables with outcome. Two-tailed p 5 0.05 was considered 
significant, although values of 0.05 < p < 0.10 are included 
for completeness (12). Multivariate logistic regression anal- 
yses with alpha to enter and remove variables = 0.15 (13) 
were used to test hypotheses regarding the independent 
effect of variables on the in-hospital mortality rate. To test 
the independent effect of angioplasty success on the mortal- 
ity rate after the contribution of other important predictors 
of outcome, a final multivariate analysis was performed, first 
forcing the previously significant variables into the equation 
(14,15), and then entering angioplasty outcome into the 
model. 
1124 ELLIS ET AL. JACC Vol. 13, No. 5 
ANGIOPLASTY FOR ACUTE MYOCARDIAL INFARCTION April 1989: 1122-6 
Table 1. Patient and Coronary Stenosis Characteristics 
Early PTCA Late PTCA 
(n = 117) (n = 139) p Value 
Table 2. Initial Coronary 
In-Hospital Events* 
Angioplasty Results and 
Early Late 
PTCA PTCA 
(n = 117) (n = 139) 
Postangioplasty diameter stenosis (%) 55 + 21 52 f 27 
Successful angioplasty (%)t 71.8 18.4 
Postangioplasty arterial patency (%)$ 78.6 82.7 
Predischarge angiography (%) 60.9 54.0 
Recurrent ischemia (%)§ 22.8 15.6 
Emergency bypass surgery (%) 1.7 3.6 
Improvement in LVEF (%) 11 2.2 + 8.8 0.9 2 9.9 
In-hospital mortality (%) 13.7 13.7 
*There were no significant (p 5 0.05) differences between the two patient 
Age (yr) 
Gender (% male) 
Time to PTCA (h) 
(median, range) 
Prior infarction (%) 
Diabetes mellitus (%) 
Anterior infarction (%) 
Multivessel disease (%) 
Systolic blood pressure at 
catheterization (mm Hg) 
Cardiogenic shock (%) 
LVEF (%) 





Diameter stenosis before 
PCTA (%) 
58? 11 51* 12 NS 
82.1 69.8 0.02 
4.5 (1.5 to 5.9) I5 (6 to 48) 10.001 
17.9 25.5 NS 
7.4 19.4 0.003 
47.0 55.4 NS 
48.1 61.2 0.05 
116 * 25 112 + 21 NS 
11.2 
492 11 
45.3 56.1 NS 
9.4 10.8 NS 
42.1 31.6 NS 
2.6 1.4 NS 
93 + 13 942 10 NS 
14.4 NS 
44 + 12 0.001 
LAD = left anterior descending coronary artery; LCx = left circumflex 
coronary artery; LVEF = left ventricular ejection fraction; NS = not 
significant; PTCA = percutaneous transluminal coronary angioplasty; RCA = 
right coronary artery. 
Results 
Patient characteristics. The characteristics of the 256 
patients and the coronary stenosis dilated in both the time 0 
to 5.9 h (early) (n = 139) and 6 to 48 h (late) (n = 117) 
angioplasty groups are enumerated in Table 1. Because of 
the selection pressures noted in the previous section, the 
groups differed slightly in patient composition. In general, 
patients with late angioplasty had more extensive disease 
and more severe left ventricular dysfunction. 
Initial angioplasty results and in-hospital events for early 
and late angioplasty groups (Table 2). There were no differ- 
ences between the groups in terms of procedural success, 
improvement in ejection fraction, recurrent ischemia after 
apparently successful angioplasty or incidence of in-hospital 
death. When late angioplasty was successful, the mortality 
rate was 5.5%, but when it was unsuccessful, it was 43.3% 
(p < 0.001). 
Correlates of in-hospital mortality for all patients treated 
(Table 3). Of the variables tested, seven were significant 
univariate predictors of increased in-hospital mortality rate: 
cardiogenic shock (p < O.OOl), unsuccessful angioplasty (p < 
O.OOl), low left ventricular ejection fraction (p < O.OOl), 
patient age (p < O.OOl), total occlusion before angioplasty (p 
= 0.003), prior myocardial infarction (p = 0.03) and triple 
vessel coronary artery disease (p = 0.055). In multivariate 
testing, there were four independent predictors of the in- 
hospital mortality rate: cardiogenic shock, unsuccessful 
angioplasty, low ejection fraction and patient age. 
groups; Wnal diameter stenosis ~70% and Thrombolysis in Myocardial 
Infarction (TIMI) flow grade 22; *final TIM1 flow grade ~2; @patients with 
predischarge angioplasty, emergency bypass surgery or second creatine 
kinase increase; 11 from baseline to predischarge ventriculography. 
Effect of time to angioplasty on influence of successful 
angioplasty on mortality rate. Time to angioplasty was 
weakly correlated with the incidence of in-hospital death in 
univariate testing (coefficient = 0.003, constant = 0.099, p = 
0.08). Time was then entered into a multivariate analysis 
utilizing both the early- and late-treated patients with the 
following independent variables: cardiogenic shock, ejection 
fraction, angioplasty success, patient age and time from the 
onset of chest pain to angioplasty, and with mortality as the 
end point (Table 3). Cardiogenic shock, angioplasty success, 
low ejection fraction and patient age were independent 
predictors of outcome, whereas time from the onset of chest 
pain (p = 0.56) was not a predictor of outcome. 
Causes and timing of in-hospital death after late angio- 
plasty. Because of the high mortality (13 of 30 = 43%) of 
patients with unsuccessful late angioplasty, these 13 patients 
were characterized separately and compared with the 30 
who survived a failed angioplasty procedure. Of the 13 
patients who died, 9 (69%) were men, their mean age was 62 
? 10 years, 10 (77%) had anterior infarction and the mean 
time to angioplasty was 20 ? 17 h. Death occurred 42 + 52 
h (median 6 h) after angioplasty, with four deaths occurring 
in the catheterization laboratory. Eleven of the 13 deaths 
(84.5%) were attributed to cardiogenic shock. The mean 
peak creatine kinase concentration was 1,281 + 432 U/liter, 
but the actual peak may have been missed as a result of late 
hospitalization in some patients. Transient reperfusion had 
been achieved in eight patients (61.5%). The statistical 
power for detecting significant differences between those 
dying and surviving was low because of the small number of 
patients involved, but those dying had a lower ejection 
fraction (30 ? 8% versus 43 ? 16%, p = 0.015) and more 
frequently had anterior infarction (77% versus 41%, p = 
0.05). In addition, these patients tended to be older (62 -+ 10 
versus 55 +- 12 years), to have had lower blood pressure at 
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Table 3. Correlates and Effect of Time to Coronary Angioplasty on In-Hospital Mortality 





Time to PTCA 
Constant 
0.292 0.052 5.51 <O.OOl 
-0.146 0.042 -3.53 0.001 
-0.005 0.002 -3.20 0.002 
0.004 0.001 2.91 0.004 
0.001 0.002 0.58 O.S62 
0.163 0.130 1.26 0.2 IO 
Abbreviations as in Table I. 
presentation (92 2 20 versus 107 +- 21 mm Hg), to have been 
diabetic (38.5% versus 17.5%), to have had total occlusion of 
the infarct artery (92% versus 70.5%), to have had multives- 
se1 disease (77% versus 59%) and to have had no collateral 
flow to the infarct-related artery (23% versus 42%). Nec- 
ropsy study of three patients revealed that one had a grossly 
hemorrhagic infarct with free wall rupture, another had a 
hemorrhagic infarct and the third had a nonhemorrhagic 
infarct but had not exhibited transient reperfusion. 
Six patients (5.5%) died after initially successful angio- 
plasty. Four of the six patients were men (mean age 68 ? 7 
years) and five had anterior wall infarction; the ejection 
fraction was 34 ? 6%, the mean time to angioplasty 20 5 18 
h and peak creatine kinase 5,580 ? 2,988 U/liter. Four deaths 
were attributed to cardiogenic shock; two deaths were 
sudden. Necropsy studies were performed in two patients: 
both had hemorrhagic transmural infarction, and one had a 
nontransmural free wall tear. 
Discussion 
Up to 25% to 32% of patients with acute myocardial 
infarction present to medical care facilities relatively late in 
the course of myocardial infarction (2,3,16,17) and are 
unlikely to have substantial infarct size reduction even if 
coronary artery blood flow can be reestablished (18). How- 
ever, recent studies (2,3) suggest that early reperfusion and 
presumed infarct size reduction may not be a prerequisite for 
improved survival after infarction treated with thrombolytic 
agents. The basis for improved survival under such circum- 
stances may be a decrease in lethal arrhythmias (4) or a 
reduction of infarct expansion (5). The latter might be due to 
salvage of an epicardial rim of tissue in patients with 
relatively high ischemic area blood flow (18,19) or perhaps 
an early reduction of ventricular afterload (20) because of the 
vasodilating effect of streptokinase (21). 
Likelihood of angioplasty success. Although in this study 
patients with late angioplasty had a greater incidence of high 
risk coronary anatomy and worse left ventricular function 
than did the early angioplasty group, procedural success and 
rates of later in-hospital ischemic events did not differ 
between the two groups. This would imply that early throm- 
bus maturation is not an impediment to successful angio- 
plasty, and would seem to confirm that the primary angio- 
plasty result, not the age of the occlusive or partially 
occlusive thrombus, is the primary determinant of the risk of 
later in-hospital recurrent ischemia (22). These results are in 
agreement with those reported by Yeager et al. (23) in the 
only other reported sizable series of this kind, except that in 
our analysis, left ventricular ejection fraction did not in- 
crease from baseline to prehospital discharge in either the 
early or the late angioplasty group. 
Effect of angioplasty on patient survival. Successful late 
angioplasty conferred a relative survival advantage to pa- 
tients even after consideration of other important predictors 
of outcome. This was not a randomized trial of late angio- 
plasty versus conventional therapy, however, and one can- 
not exclude the possibility that failed angioplasty increased 
the likelihood of in-hospital death, especially given the high 
mortality rates in patients with failed angioplasty relative to 
historical control patients presenting late, who were treated 
without reperfusion (mortality rate with successful late 
angioplasty = 5.5%, with unsuccessful angioplasty = 43.3%. 
overall = 13.7% versus 13.9%) in 961 patients presenting 6 to 
12 h after symptom onset in the Gruppo Italian0 per lo 
Studio della Streptochinasi nell’lnfarto Miocardico (GISSI) 
trial (16). A truly appropriate “control” group is, unfortu- 
nately, not available, and patients in the GISSI trial probably 
had a lower overall risk than did the patients treated late in 
this study (2% cardiogenic shock in all GISSI patients versus 
14% in this study, 15% incidence of prior myocardial infarc- 
tion in GISSI versus 25% in this study). 
Potential risk of late reperfusion. Experimental studies 
would suggest that delayed reperfusion might well be a 
“double-edged sword” (24), increasing the risk of hemor- 
rhagic infarction, with its potential consequent deleterious 
mechanical and functional effects (25,27). Of note, two of the 
five patients who underwent necropsy in this series had a 
hemorrhagic tear of the free wall of the left ventricle. 
Nonetheless, the mortality rates in this series for patients 
with successful angioplasty are less than one would expect 
from conventionally treated patients. 
Limitations. The primary limitations of this study are the 
lack of a medically treated control group and the relatively 
small numbers of patients studied. Therefore, one cannot 
necessarily conclude that successful angioplasty improved 
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patient survival because failed angioplasty may have dimin- 
ished survival and factors other than those assessed in 
multivariable testing also may have influenced outcome. 
Implications. In conjunction with other similarly provoc- 
ative study results (2,3), these results suggest the need for a 
randomized trial investigating a possible survival benefit of 
delayed reperfusion in certain patients with acute myocar- 
dial infarction. However, the high mortality rate with failed 
angioplasty in this series suggests that more needs to be 
learned about which patients may be harmed by angioplasty 
and the mechanism by which mortality is increased. Until 
the results of such a randomized trial are known, patients 65 
years old or younger with total coronary occlusion present- 
ing 6 to 48 h after the onset of a large acute myocardial 
infarction with continued ischemia or hemodynamic com- 
promise should not necessarily be denied coronary angio- 
plasty or perhaps other forms of reperfusion therapy. How- 
ever, given the mortality rates in patients with failed 
angioplasty, a high likelihood of success should be expected 
before this intervention is performed. 
We thank Judy Hanson for expert secretarial assistance in preparing this 
manuscript. 
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